Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.58 |
| ▸ | CASR | P41180 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14358463 | 1.00 | ENPP2 (0.58) | ENPP2CASRHPGDALDH1A1KDM4C | |
| SCHEMBL15105399 | 0.91 | ENPP2 (0.61) | ENPP2HPGDALDH1A1KDM4CKMT2A | |
| SCHEMBL14361795 | 0.91 | ENPP2 (0.61) | ENPP2HPGDALDH1A1KDM4CKMT2A | |
| SCHEMBL14358637 | 0.89 | ENPP2 (0.71) | ENPP2CASRRAD51MTNR1B | |
| SCHEMBL14358655 | 0.89 | ENPP2 (0.71) | ENPP2CASRRAD51MTNR1B | |
| SCHEMBL19210838 | 0.89 | RAD51 (0.53) | ENPP2HPGDALDH1A1KDM4CKMT2A | |
| SCHEMBL14358475 | 0.86 | ENPP2 (0.70) | ENPP2HPGDALDH1A1KDM4CKMT2A | |
| SCHEMBL14358468 | 0.86 | ENPP2 (0.70) | ENPP2HPGDALDH1A1KDM4CKMT2A | |
| SCHEMBL14358743 | 0.86 | ENPP2 (0.57) | ENPP2CASRHPGDALDH1A1KDM4C | |
| SCHEMBL14358749 | 0.86 | ENPP2 (0.57) | ENPP2CASRHPGDALDH1A1KDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10207988-B2 | Methods and compositions for treatment of cancer and autoimmune disease | THE JACKSON LABORATORY (US) | 2019-02-19 | — | — | US | claimed |
| EP-2724156-B1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE | JACKSON LAB (US) | 2017-08-16 | — | — | EP | claimed |
| EP-2724156-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE | The Jackson Laboratory (US) | 2014-04-30 | — | — | EP | claimed |
| US-20130184342-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE | THE JACKSON LABORATORY (US) | 2013-07-18 | — | — | US | claimed |
| WO-2013003112-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE | THE JACKSON LABORATORY (US) | 2013-01-03 | — | — | WO | claimed |
| US-10207988-B2 | Methods and compositions for treatment of cancer and autoimmune disease | THE JACKSON LABORATORY (US) | 2019-02-19 | — | — | US | disclosed |
| EP-2724156-B1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE | JACKSON LAB (US) | 2017-08-16 | — | — | EP | disclosed |
| EP-2724156-B1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE | JACKSON LAB (US) | 2017-08-16 | — | — | EP | disclosed |
| EP-2724156-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE | The Jackson Laboratory (US) | 2014-04-30 | — | — | EP | disclosed |
| US-20130184342-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE | THE JACKSON LABORATORY (US) | 2013-07-18 | — | — | US | disclosed |
| WO-2013003112-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE | THE JACKSON LABORATORY (US) | 2013-01-03 | — | — | WO | disclosed |
| WO-2013003112-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE | THE JACKSON LABORATORY (US) | 2013-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184342-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE | BAK1, SSB, MRE11 | ENPP2 100/4885CASR 4164/4885HPGD 1545/4885 |
| US-10207988-B2 | Methods and compositions for treatment of cancer and autoimmune disease | BAK1, SSB, MRE11 | ENPP2 100/4885CASR 4164/4885HPGD 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.